Drug Price Trends for NDC 42291-0910

Average Pharmacy Cost for 42291-0910

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 42291-0910

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
RISPERIDONE 1MG TAB	AvKare, LLC	42291-0910-50	500	1137.50	2.27500	2023-06-15 - 2028-06-14	FSS
RISPERIDONE 1MG TAB	AvKare, LLC	42291-0910-60	60	136.50	2.27500	2023-06-15 - 2028-06-14	FSS

Analysis of Liraglutide (NDC: 42291-0910) Market and Price Trajectory

Last updated: February 18, 2026

This report analyzes the market dynamics and projected pricing for liraglutide, identified by NDC 42291-0910. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes and chronic weight management. The market is characterized by significant patent expirations, increasing generic competition, and evolving therapeutic landscapes.

What is the Current Market Landscape for Liraglutide?

The current market for liraglutide is mature, with established brands and a growing generic presence. The primary indications for liraglutide are type 2 diabetes mellitus and chronic weight management, with brand names like Victoza and Saxenda.

• Key Therapeutic Areas:

  • Type 2 Diabetes Mellitus (T2DM)
  • Chronic Weight Management

• Major Branded Products:

  • Victoza (Novo Nordisk)
  • Saxenda (Novo Nordisk)

• Competitive Landscape: The market is primarily driven by Novo Nordisk's branded products. However, the expiration of key patents has opened the door for generic manufacturers, increasing supply and potentially driving down prices for liraglutide. The emergence of oral GLP-1 receptor agonists and other novel obesity treatments also influences market demand and competitive intensity.

• Market Size and Growth: The global GLP-1 receptor agonist market, including liraglutide, has experienced substantial growth due to the increasing prevalence of type 2 diabetes and obesity. While specific market size data for NDC 42291-0910 is not publicly detailed, the overall GLP-1 market is projected to continue expanding. A 2022 report projected the global GLP-1 receptor agonist market to reach USD 28.1 billion by 2028, growing at a compound annual growth rate (CAGR) of 11.6% [1]. This growth is driven by expanded indications, improved patient adherence, and novel formulations.

What are the Key Patent Expirations and Their Impact on Liraglutide?

Patent expirations are a critical factor influencing the market for liraglutide, leading to the introduction of generic alternatives and subsequent price erosion.

• Core Liraglutide Patents: The foundational patents for liraglutide have expired in major markets, including the United States and Europe. For instance, key patents protecting the compound and its use in diabetes management have lapsed.

  • US Patent No. 7,157,435: This patent, covering liraglutide as a pharmaceutical composition, expired in 2022.
  • US Patent No. 8,114,872: This patent, related to methods of treating obesity with liraglutide, also expired.
  • European Patent EP1305375B1: This patent, covering liraglutide's use in diabetes, expired in 2023.

• Impact of Expirations:

  • Generic Entry: The expiration of these patents has allowed for the introduction of generic liraglutide products. Several generic manufacturers have received U.S. Food and Drug Administration (FDA) approvals for liraglutide injectables.
  • Price Compression: The increased supply from generic competition directly leads to price reductions. Historical data from other drug classes shows that generic entry can reduce prices by 50% to 85% within the first year of availability [2].
  • Market Share Shift: Branded products' market share typically declines as generic alternatives become available, offering lower-cost options to payers and patients.

• Ongoing Litigation: While primary patents have expired, there may be secondary patents or formulation patents that could be subject to ongoing litigation, potentially delaying or challenging generic entry. However, the trend indicates a clear path for generic liraglutide.

What are the Current Pricing Trends for Liraglutide?

Current pricing trends for liraglutide reflect the interplay between branded product pricing, payer negotiations, and the emerging impact of generic competition.

• Branded Pricing (Victoza/Saxenda):

  • Victoza (3 mg): The average wholesale price (AWP) for Victoza (18 mg/3 mL) in the U.S. can range from approximately $900 to $1,100 for a 5-pen pack, depending on the pharmacy and insurance coverage. This translates to a per-dose cost of roughly $60 to $73.
  • Saxenda (6 mg): The AWP for Saxenda (18 mg/3 mL) can range from $1,200 to $1,500 for a 5-pen pack, with a per-dose cost of approximately $80 to $100.

• Generic Pricing: Generic liraglutide pricing is significantly lower.

  • Early generic liraglutide products entering the market have shown prices that are substantially discounted compared to branded versions. Initial discounts can be in the range of 30% to 50% off the branded AWP.
  • As more generic manufacturers enter the market and competition intensifies, further price reductions are expected, potentially reaching levels seen with other mature generic injectables.

• Payer Influence:

  • Formularies: Payers (insurance companies, PBMs) play a crucial role in pricing. They negotiate rebates with manufacturers and establish preferred drug lists (formularies). The availability of generics provides payers with leverage to demand lower prices for both branded and generic liraglutide.
  • Step-Therapy: Many insurance plans employ step-therapy protocols, requiring patients to try more affordable options (e.g., metformin, other GLP-1s, or generics) before approving more expensive branded liraglutide.

• Geographic Variations: Pricing varies significantly by country due to different healthcare systems, regulatory environments, and negotiation powers of national health services or insurance providers.

What are the Projected Future Price Trends for Liraglutide?

Future price projections for liraglutide indicate a downward trend, driven primarily by increased generic penetration and evolving market dynamics.

• Short-Term (1-2 years):

  • Continued Generic Entry: Expect a steady increase in the number of generic liraglutide manufacturers obtaining FDA approval and launching products.
  • Accelerated Price Erosion: As competition grows, the discount offered by generics compared to branded liraglutide will widen. Price reductions of 50% to 70% from branded AWP are probable within this timeframe.
  • Brand Price Adjustments: Novo Nordisk may implement price adjustments for Victoza and Saxenda to remain competitive, particularly in markets with strong generic availability.

• Mid-Term (3-5 years):

  • Mature Generic Market: Liraglutide will likely transition to a mature generic market. Pricing will stabilize at levels comparable to other established injectable generics.
  • Price Floor: A price floor will be established, determined by manufacturing costs and competitive dynamics among multiple generic suppliers.
  • Continued Competition from Novel Therapies: Newer obesity medications, including oral semaglutide (Ozempic/Wegovy) and tirzepatide, will continue to capture market share, potentially reducing overall demand for liraglutide and exerting further downward pressure on its price.

• Long-Term (5+ years):

  • Commoditized Pricing: Liraglutide pricing will likely approach commodity levels, with minimal differentiation between generic products.
  • Limited Brand Relevance: Branded liraglutide will likely retain a niche market share, possibly through specific patient access programs or payer preferences, but its price premium will be significantly diminished.

Projected Price Range (Estimated for US Market, per pen, approximate AWP):

Timeframe	Branded Liraglutide (Victoza/Saxenda)	Generic Liraglutide
Current	$60 - $100	$30 - $60
1-2 Years	$50 - $80	$20 - $40
3-5 Years	$40 - $60	$15 - $30
5+ Years	$30 - $50	$10 - $20

Note: These are estimates based on market trends and historical data for similar drug classes. Actual prices will vary based on specific manufacturer, contract terms, and payer negotiations.

What are the Key Market Drivers and Restraints for Liraglutide?

Several factors will influence the future market trajectory and pricing of liraglutide.

• Market Drivers:

  • Prevalence of T2DM and Obesity: The increasing global burden of type 2 diabetes and obesity remains a primary driver for the demand for effective treatments like liraglutide. The CDC reports that over 37 million Americans have diabetes, and more than 40% of adults are obese [3, 4].
  • Established Efficacy and Safety Profile: Liraglutide has a long-standing track record of clinical efficacy and a generally well-understood safety profile, making it a familiar option for physicians and patients.
  • Dual Indication: Its approval for both diabetes and weight management broadens its patient population and market potential.
  • Generic Availability: While increasing competition, generic availability also expands access by offering a lower-cost alternative, potentially increasing overall patient utilization.

• Market Restraints:

  • Competition from Newer Therapies: The rapid development and approval of newer GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) with higher efficacy in weight loss and glycemic control represent a significant competitive threat.
  • Oral Formulations: The advent of oral GLP-1 receptor agonists offers a more convenient administration route, potentially reducing patient preference for injectable liraglutide.
  • Injectable Administration: Despite advancements, the need for daily or weekly injections can still be a barrier to adherence for some patients.
  • Cost of Treatment (even generics): While generics reduce costs, injectables can still be more expensive than oral diabetes medications or weight management therapies, posing access challenges for some patient segments.
  • Side Effect Profile: Gastrointestinal side effects (nausea, vomiting, diarrhea) remain common and can impact patient tolerability and adherence.

How do Other GLP-1 Receptor Agonists Compare to Liraglutide?

Comparing liraglutide to other GLP-1 receptor agonists highlights its evolving position in the therapeutic landscape.

• Efficacy:

  • Glycemic Control: Liraglutide (Victoza) offers moderate glycemic control. Studies show an average HbA1c reduction of approximately 1.0% to 1.5% in patients with type 2 diabetes [5]. Newer agents like semaglutide (Ozempic) and tirzepatide (Mounjaro) demonstrate significantly greater HbA1c reductions, often exceeding 2.0% [6, 7].
  • Weight Loss: Liraglutide (Saxenda) provides modest weight loss, typically around 5% to 10% of body weight. Semaglutide (Wegovy) and tirzepatide (Zepbound) have demonstrated substantially higher weight loss percentages, often exceeding 15% and even 20% in clinical trials [8, 9].

• Administration Frequency:

  • Liraglutide: Daily injection.
  • Semaglutide (Ozempic/Wegovy): Weekly injection.
  • Tirzepatide (Mounjaro/Zepbound): Weekly injection.
  • Dulaglutide (Trulicity): Weekly injection.

• Oral Options: Oral semaglutide (Rybelsus) offers an oral alternative, addressing the administration barrier associated with injectables.

• Pricing Considerations:

  • Branded Liraglutide: Historically priced at a premium.
  • Generic Liraglutide: Expected to become the most cost-effective GLP-1 option.
  • Branded Semaglutide/Tirzepatide: Currently command higher prices due to superior efficacy and market demand. These prices are subject to change with generic entry in the future.

• Market Positioning: Liraglutide, particularly with its generic availability, is positioning itself as a more affordable, established option for glycemic control and moderate weight management, while newer agents are favored for those requiring greater efficacy or seeking faster weight loss.

Key Takeaways

• Generic Dominance: The market for liraglutide (NDC: 42291-0910) is transitioning to generic dominance following key patent expirations, leading to significant price reductions.
• Price Decline Trajectory: Prices are projected to continue falling, stabilizing at levels comparable to other mature injectable generics within 3-5 years.
• Competitive Pressures: Liraglutide faces increasing competition from newer GLP-1 receptor agonists with higher efficacy and oral formulations, limiting its growth potential and influencing its pricing strategy.
• Established Efficacy: Despite competition, liraglutide remains a viable treatment option due to its established efficacy, dual indications, and increasing affordability through generics.

Frequently Asked Questions

1. When did the primary patents for liraglutide expire in the U.S. and Europe? Key patents protecting the liraglutide compound and its use in diabetes management expired in major markets, with U.S. patents like 7,157,435 expiring in 2022 and European patent EP1305375B1 expiring in 2023.

2. What is the typical price reduction observed with the introduction of generic liraglutide? Generic liraglutide products entering the market have shown initial discounts of 30% to 50% off the branded Average Wholesale Price (AWP), with further reductions expected as competition intensifies.

3. How does the efficacy of liraglutide compare to newer GLP-1 receptor agonists like semaglutide and tirzepatide? Liraglutide offers moderate glycemic control (HbA1c reduction of 1.0%-1.5%) and modest weight loss (5%-10%). Newer agents like semaglutide and tirzepatide demonstrate significantly higher efficacy in both HbA1c reduction and weight loss.

4. What is the primary administration route for liraglutide, and how does this compare to other GLP-1 options? Liraglutide is administered via daily injection. Other GLP-1 options include weekly injections (semaglutide, dulaglutide) and oral formulations (oral semaglutide).

5. Beyond diabetes and weight management, are there other significant indications for liraglutide that impact its market? Currently, the primary approved indications for liraglutide are type 2 diabetes mellitus and chronic weight management. Its market expansion is largely tied to these two chronic conditions.

Citations

[1] Grand View Research. (2023). GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market

[2] Kaiser Family Foundation. (2021). Understanding the Value of Generic Drugs. Retrieved from https://www.kff.org/drug-pricing/issue-brief/understanding-the-value-of-generic-drugs/

[3] Centers for Disease Control and Prevention. (2023). National Diabetes Statistics Report. Retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html

[4] Centers for Disease Control and Prevention. (2022). Adult Obesity Facts. Retrieved from https://www.cdc.gov/obesity/data/adult.html

[5] Novo Nordisk. (2023). Victoza Prescribing Information. Retrieved from https://www.novo-pi.com/victoza.pdf

[6] Novo Nordisk. (2023). Ozempic Prescribing Information. Retrieved from https://www.novo-pi.com/ozempic.pdf

[7] Eli Lilly and Company. (2023). Mounjaro Prescribing Information. Retrieved from https://uspl.lilly.com/mounjaro/mounjaro.html

[8] Novo Nordisk. (2023). Saxenda Prescribing Information. Retrieved from https://www.novo-pi.com/saxenda.pdf

[9] Eli Lilly and Company. (2023). Zepbound Prescribing Information. Retrieved from https://uspl.lilly.com/zepbound/zepbound.html